Late-Breaking Abstract on LB-100, Lixte Biotechnology''s Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
(firmenpresse) - EAST SETAUKET, NY -- (Marketwired) -- 03/09/17 -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that a late-breaking abstract entitled "Protein phosphatase 2A inhibition with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD-1 blockade in a preclinical model" has been accepted for presentation as a poster (abstract number LB-193) at the American Association for Cancer Research Annual Meeting 2017 in Washington, DC on April 4th.
Dr. John S. Kovach, Founder and CEO of Lixte, said, "The new preclinical research studies were done by Lixte and scientists at the , National Institutes of Health (NIH), under a Cooperative Research and Development Agreement." Dr. Kovach continued, "LB-100 used alone has recently completed a Phase 1 trial in patients with advanced cancer ()."
Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte''s product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company''s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company''s filings with the United States Securities and Exchange Commission at .
Eric J. Forman, Esq.
646-894-3135
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.03.2017 - 09:30 Uhr
Sprache: Deutsch
News-ID 1491717
Anzahl Zeichen: 2070
contact information:
Contact person:
Town:
EAST SETAUKET, NY
Phone:
Kategorie:
Venture Capital
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 342 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Late-Breaking Abstract on LB-100, Lixte Biotechnology''s Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
"
steht unter der journalistisch-redaktionellen Verantwortung von
Lixte Biotechnology Holdings, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
